In Vivo Targeting Replication Protein A for Cancer Therapy

Replication protein A (RPA) plays essential roles in DNA replication, repair, recombination, and the DNA damage response (DDR). Retrospective analysis of lung cancer patient data demonstrates high RPA expression as a negative prognostic biomarker for overall survival in smoking-related lung cancers. Similarly, relative expression of RPA is a predictive marker for response to chemotherapy. These observations are consistent with the increase in RPA expression serving as an adaptive mechanism that allows tolerance of the genotoxic stress resulting from carcinogen exposure. We have developed second-generation RPA inhibitors (RPAis) that block the RPA–DNA interaction and optimized formulation for in vivo analyses. Data demonstrate that unlike first-generation RPAis, second-generation molecules show increased cellular permeability and induce cell death via apoptosis. Second-generation RPAis elicit single-agent in vitro anticancer activity across a broad spectrum of cancers, and the cellular response suggests existence of a threshold before chemical RPA exhaustion induces cell death. Chemical RPA inhibition potentiates the anticancer activity of a series of DDR inhibitors and traditional DNA-damaging cancer therapeutics. Consistent with chemical RPA exhaustion, we demonstrate that the effects of RPAi on replication fork dynamics are similar to other known DDR inhibitors. An optimized formulation of RPAi NERx 329 was developed that resulted in single-agent anticancer activity in two non-small cell lung cancer models. These data demonstrate a unique mechanism of action of RPAis eliciting a state of chemical RPA exhaustion and suggest they will provide an effective therapeutic option for difficult-to-treat lung cancers.

[1]  C. Lord,et al.  Targeting the DNA damage response in immuno-oncology: developments and opportunities , 2021, Nature Reviews Cancer.

[2]  S. Cantor,et al.  Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency. , 2021, Molecular cell.

[3]  J. Soria,et al.  Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study , 2021, Clinical Cancer Research.

[4]  S. Cantor,et al.  Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency. , 2021, Molecular cell.

[5]  Navnath S. Gavande,et al.  Chemical exhaustion of RPA in cancer treatment , 2020, bioRxiv.

[6]  Navnath S. Gavande,et al.  Discovery and development of novel DNA-PK inhibitors by targeting the unique Ku–DNA interaction , 2020, bioRxiv.

[7]  Navnath S. Gavande,et al.  Discovery and Development of Novel DNA-PK Inhibitors by Targeting the unique Ku-DNA Interaction , 2020, bioRxiv.

[8]  Navnath S. Gavande,et al.  Structure-Guided Optimization of Replication Protein A (RPA)-DNA Interaction Inhibitors. , 2020, ACS medicinal chemistry letters.

[9]  A. A. Demin,et al.  The Importance of Poly(ADP-Ribose) Polymerase as a Sensor of Unligated Okazaki Fragments during DNA Replication , 2018, Molecular cell.

[10]  B. Goh,et al.  Third generation EGFR TKIs: current data and future directions , 2018, Molecular Cancer.

[11]  Navnath S. Gavande,et al.  Modulating DNA Repair Pathways to Improve Precision Genome Engineering. , 2017, ACS chemical biology.

[12]  Navnath S. Gavande,et al.  Design and Structure-Guided Development of Novel Inhibitors of the Xeroderma Pigmentosum Group A (XPA) Protein-DNA Interaction. , 2017, Journal of medicinal chemistry.

[13]  J. Lukas,et al.  Replication Catastrophe: When a Checkpoint Fails because of Exhaustion. , 2017, Molecular cell.

[14]  R. Schwab,et al.  The DNA fibre technique - tracking helicases at work. , 2016, Methods.

[15]  H. Zhang,et al.  Identification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells , 2016, Oncotarget.

[16]  J. Debreczeni,et al.  Cellular Active N-Hydroxyurea FEN1 Inhibitors Block Substrate Entry to the Active Site , 2016, Nature chemical biology.

[17]  Navnath S. Gavande,et al.  DNA repair targeted therapy: The past or future of cancer treatment? , 2016, Pharmacology & therapeutics.

[18]  Alan Ashworth,et al.  Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. , 2015, Annual review of medicine.

[19]  N. Mailand,et al.  ATR Prohibits Replication Catastrophe by Preventing Global Exhaustion of RPA , 2013, Cell.

[20]  M. Dimopoulos,et al.  Replication Protein A in Nonearly Ovarian Adenocarcinomas: Correlation With MCM-2, MCM-5, Ki-67 Index and Prognostic Significance , 2012, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[21]  S. Jalal,et al.  Novel Irreversible Small Molecule Inhibitors of Replication Protein A Display Single-Agent Activity and Synergize with Cisplatin , 2011, Molecular Cancer Therapeutics.

[22]  P. Korkolopoulou,et al.  Prognostic significance of replication protein A (RPA) expression levels in bladder urothelial carcinoma , 2011, BJU international.

[23]  J. Turchi,et al.  Targeting the OB-Folds of Replication Protein A with Small Molecules , 2010, Journal of nucleic acids.

[24]  J. Turchi,et al.  Identification of novel small molecule inhibitors of the XPA protein using in silico based screening. , 2010, ACS chemical biology.

[25]  J. Turchi,et al.  Targeted inhibition of Replication Protein A reveals cytotoxic activity, synergy with chemotherapeutic DNA-damaging agents, and insight into cellular function. , 2010, Cancer research.

[26]  T. Helleday,et al.  Hydroxyurea-Stalled Replication Forks Become Progressively Inactivated and Require Two Different RAD51-Mediated Pathways for Restart and Repair , 2010, Molecular cell.

[27]  G. Simon Individualizing Chemotherapy for Non-small Cell Lung Cancer (NSCLC) in the Adjuvant and Advanced Setting: Current Status and Future Directions , 2008, Current treatment options in oncology.

[28]  A. Mason,et al.  Cellular Functions of Human RPA1 , 2008, Journal of Biological Chemistry.

[29]  G. Kouraklis,et al.  Replication protein A is an independent prognostic indicator with potential therapeutic implications in colon cancer , 2007, Modern Pathology.

[30]  Hongbing Shen,et al.  Smoking, DNA repair capacity and risk of nonsmall cell lung cancer , 2003, International journal of cancer.

[31]  M. Spitz,et al.  Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. , 2000, Journal of the National Cancer Institute.

[32]  T. Taguchi,et al.  [Phase I study]. , 1995, Gan to kagaku ryoho. Cancer & chemotherapy.

[33]  J. Turchi,et al.  Chemical inhibitor targeting the replication protein A-DNA interaction increases the efficacy of Pt-based chemotherapy in lung and ovarian cancer. , 2015, Biochemical pharmacology.

[34]  Stuart Moss,et al.  Current Status and Future Directions , 2013 .